Effect of Ser-129 phosphorylation on interaction of α-synuclein with synaptic and cellular membranes.
Identifieur interne : 000B63 ( PubMed/Curation ); précédent : 000B62; suivant : 000B64Effect of Ser-129 phosphorylation on interaction of α-synuclein with synaptic and cellular membranes.
Auteurs : Naomi P. Visanji [Canada] ; Sabine Wislet-Gendebien ; Loren W. Oschipok ; Gang Zhang ; Isabelle Aubert ; Paul E. Fraser ; Anurag TandonSource :
- The Journal of biological chemistry [ 1083-351X ] ; 2011.
English descriptors
- KwdEn :
- Amino Acid Substitution, Animals, Cell Line, Epitopes (genetics), Epitopes (metabolism), Humans, Lewy Bodies (genetics), Lewy Bodies (metabolism), Mice, Mice, Knockout, Mutation, Missense, Parkinsonian Disorders (genetics), Parkinsonian Disorders (metabolism), Protein Binding (genetics), Protein Kinases (biosynthesis), Protein Kinases (genetics), Protein Transport (genetics), Protein-Serine-Threonine Kinases (biosynthesis), Protein-Serine-Threonine Kinases (genetics), Synaptic Membranes (genetics), Synaptic Membranes (metabolism), alpha-Synuclein (genetics), alpha-Synuclein (metabolism).
- MESH :
- chemical , biosynthesis : Protein Kinases, Protein-Serine-Threonine Kinases.
- chemical , genetics : Epitopes, Protein Kinases, Protein-Serine-Threonine Kinases, alpha-Synuclein.
- chemical , metabolism : Epitopes, alpha-Synuclein.
- genetics : Lewy Bodies, Parkinsonian Disorders, Protein Binding, Protein Transport, Synaptic Membranes.
- metabolism : Lewy Bodies, Parkinsonian Disorders, Synaptic Membranes.
- Amino Acid Substitution, Animals, Cell Line, Humans, Mice, Mice, Knockout, Mutation, Missense.
Abstract
In the healthy brain, less than 5% of α-synuclein (α-syn) is phosphorylated at serine 129 (Ser(P)-129). However, within Parkinson disease (PD) Lewy bodies, 89% of α-syn is Ser(P)-129. The effects of Ser(P)-129 modification on α-syn distribution and solubility are poorly understood. As α-syn normally exists in both membrane-bound and cytosolic compartments, we examined the binding and dissociation of Ser(P)-129 α-syn and analyzed the effects of manipulating Ser(P)-129 levels on α-syn membrane interactions using synaptosomal membranes and neural precursor cells from α-syn-deficient mice or transgenic mice expressing human α-syn. We first evaluated the recovery of the Ser(P)-129 epitope following either α-syn membrane binding or dissociation. We demonstrate a rapid turnover of Ser(P)-129 during both binding to and dissociation from synaptic membranes. Although the membrane binding of WT α-syn was insensitive to modulation of Ser(P)-129 levels by multiple strategies (the use of phosphomimic S129D and nonphosphorylated S129A α-syn mutants; by enzymatic dephosphorylation of Ser(P)-129 or proteasome inhibitor-induced elevation in Ser(P)-129; or by inhibition or stable overexpression of PLK2), PD mutant Ser(P)-129 α-syn showed a preferential membrane association compared with WT Ser(P)-129 α-syn. Collectively, these data suggest that phosphorylation at Ser-129 is dynamic and that the subcellular distribution of α-syn bearing PD-linked mutations, A30P or A53T, is influenced by the phosphorylation state of Ser-129.
DOI: 10.1074/jbc.M111.253450
PubMed: 21849493
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000B63
Links to Exploration step
pubmed:21849493Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effect of Ser-129 phosphorylation on interaction of α-synuclein with synaptic and cellular membranes.</title><author><name sortKey="Visanji, Naomi P" sort="Visanji, Naomi P" uniqKey="Visanji N" first="Naomi P" last="Visanji">Naomi P. Visanji</name><affiliation wicri:level="1"><nlm:affiliation>Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Ontario M5S 3H2, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Ontario M5S 3H2</wicri:regionArea></affiliation></author><author><name sortKey="Wislet Gendebien, Sabine" sort="Wislet Gendebien, Sabine" uniqKey="Wislet Gendebien S" first="Sabine" last="Wislet-Gendebien">Sabine Wislet-Gendebien</name></author><author><name sortKey="Oschipok, Loren W" sort="Oschipok, Loren W" uniqKey="Oschipok L" first="Loren W" last="Oschipok">Loren W. Oschipok</name></author><author><name sortKey="Zhang, Gang" sort="Zhang, Gang" uniqKey="Zhang G" first="Gang" last="Zhang">Gang Zhang</name></author><author><name sortKey="Aubert, Isabelle" sort="Aubert, Isabelle" uniqKey="Aubert I" first="Isabelle" last="Aubert">Isabelle Aubert</name></author><author><name sortKey="Fraser, Paul E" sort="Fraser, Paul E" uniqKey="Fraser P" first="Paul E" last="Fraser">Paul E. Fraser</name></author><author><name sortKey="Tandon, Anurag" sort="Tandon, Anurag" uniqKey="Tandon A" first="Anurag" last="Tandon">Anurag Tandon</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2011">2011</date><idno type="RBID">pubmed:21849493</idno><idno type="pmid">21849493</idno><idno type="doi">10.1074/jbc.M111.253450</idno><idno type="wicri:Area/PubMed/Corpus">000B63</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000B63</idno><idno type="wicri:Area/PubMed/Curation">000B63</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000B63</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Effect of Ser-129 phosphorylation on interaction of α-synuclein with synaptic and cellular membranes.</title><author><name sortKey="Visanji, Naomi P" sort="Visanji, Naomi P" uniqKey="Visanji N" first="Naomi P" last="Visanji">Naomi P. Visanji</name><affiliation wicri:level="1"><nlm:affiliation>Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Ontario M5S 3H2, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Ontario M5S 3H2</wicri:regionArea></affiliation></author><author><name sortKey="Wislet Gendebien, Sabine" sort="Wislet Gendebien, Sabine" uniqKey="Wislet Gendebien S" first="Sabine" last="Wislet-Gendebien">Sabine Wislet-Gendebien</name></author><author><name sortKey="Oschipok, Loren W" sort="Oschipok, Loren W" uniqKey="Oschipok L" first="Loren W" last="Oschipok">Loren W. Oschipok</name></author><author><name sortKey="Zhang, Gang" sort="Zhang, Gang" uniqKey="Zhang G" first="Gang" last="Zhang">Gang Zhang</name></author><author><name sortKey="Aubert, Isabelle" sort="Aubert, Isabelle" uniqKey="Aubert I" first="Isabelle" last="Aubert">Isabelle Aubert</name></author><author><name sortKey="Fraser, Paul E" sort="Fraser, Paul E" uniqKey="Fraser P" first="Paul E" last="Fraser">Paul E. Fraser</name></author><author><name sortKey="Tandon, Anurag" sort="Tandon, Anurag" uniqKey="Tandon A" first="Anurag" last="Tandon">Anurag Tandon</name></author></analytic><series><title level="j">The Journal of biological chemistry</title><idno type="eISSN">1083-351X</idno><imprint><date when="2011" type="published">2011</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Amino Acid Substitution</term><term>Animals</term><term>Cell Line</term><term>Epitopes (genetics)</term><term>Epitopes (metabolism)</term><term>Humans</term><term>Lewy Bodies (genetics)</term><term>Lewy Bodies (metabolism)</term><term>Mice</term><term>Mice, Knockout</term><term>Mutation, Missense</term><term>Parkinsonian Disorders (genetics)</term><term>Parkinsonian Disorders (metabolism)</term><term>Protein Binding (genetics)</term><term>Protein Kinases (biosynthesis)</term><term>Protein Kinases (genetics)</term><term>Protein Transport (genetics)</term><term>Protein-Serine-Threonine Kinases (biosynthesis)</term><term>Protein-Serine-Threonine Kinases (genetics)</term><term>Synaptic Membranes (genetics)</term><term>Synaptic Membranes (metabolism)</term><term>alpha-Synuclein (genetics)</term><term>alpha-Synuclein (metabolism)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="biosynthesis" xml:lang="en"><term>Protein Kinases</term><term>Protein-Serine-Threonine Kinases</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Epitopes</term><term>Protein Kinases</term><term>Protein-Serine-Threonine Kinases</term><term>alpha-Synuclein</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Epitopes</term><term>alpha-Synuclein</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Lewy Bodies</term><term>Parkinsonian Disorders</term><term>Protein Binding</term><term>Protein Transport</term><term>Synaptic Membranes</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Lewy Bodies</term><term>Parkinsonian Disorders</term><term>Synaptic Membranes</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Amino Acid Substitution</term><term>Animals</term><term>Cell Line</term><term>Humans</term><term>Mice</term><term>Mice, Knockout</term><term>Mutation, Missense</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In the healthy brain, less than 5% of α-synuclein (α-syn) is phosphorylated at serine 129 (Ser(P)-129). However, within Parkinson disease (PD) Lewy bodies, 89% of α-syn is Ser(P)-129. The effects of Ser(P)-129 modification on α-syn distribution and solubility are poorly understood. As α-syn normally exists in both membrane-bound and cytosolic compartments, we examined the binding and dissociation of Ser(P)-129 α-syn and analyzed the effects of manipulating Ser(P)-129 levels on α-syn membrane interactions using synaptosomal membranes and neural precursor cells from α-syn-deficient mice or transgenic mice expressing human α-syn. We first evaluated the recovery of the Ser(P)-129 epitope following either α-syn membrane binding or dissociation. We demonstrate a rapid turnover of Ser(P)-129 during both binding to and dissociation from synaptic membranes. Although the membrane binding of WT α-syn was insensitive to modulation of Ser(P)-129 levels by multiple strategies (the use of phosphomimic S129D and nonphosphorylated S129A α-syn mutants; by enzymatic dephosphorylation of Ser(P)-129 or proteasome inhibitor-induced elevation in Ser(P)-129; or by inhibition or stable overexpression of PLK2), PD mutant Ser(P)-129 α-syn showed a preferential membrane association compared with WT Ser(P)-129 α-syn. Collectively, these data suggest that phosphorylation at Ser-129 is dynamic and that the subcellular distribution of α-syn bearing PD-linked mutations, A30P or A53T, is influenced by the phosphorylation state of Ser-129.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21849493</PMID><DateCreated><Year>2011</Year><Month>10</Month><Day>10</Day></DateCreated><DateCompleted><Year>2011</Year><Month>12</Month><Day>12</Day></DateCompleted><DateRevised><Year>2016</Year><Month>11</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1083-351X</ISSN><JournalIssue CitedMedium="Internet"><Volume>286</Volume><Issue>41</Issue><PubDate><Year>2011</Year><Month>Oct</Month><Day>14</Day></PubDate></JournalIssue><Title>The Journal of biological chemistry</Title><ISOAbbreviation>J. Biol. Chem.</ISOAbbreviation></Journal><ArticleTitle>Effect of Ser-129 phosphorylation on interaction of α-synuclein with synaptic and cellular membranes.</ArticleTitle><Pagination><MedlinePgn>35863-73</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1074/jbc.M111.253450</ELocationID><Abstract><AbstractText>In the healthy brain, less than 5% of α-synuclein (α-syn) is phosphorylated at serine 129 (Ser(P)-129). However, within Parkinson disease (PD) Lewy bodies, 89% of α-syn is Ser(P)-129. The effects of Ser(P)-129 modification on α-syn distribution and solubility are poorly understood. As α-syn normally exists in both membrane-bound and cytosolic compartments, we examined the binding and dissociation of Ser(P)-129 α-syn and analyzed the effects of manipulating Ser(P)-129 levels on α-syn membrane interactions using synaptosomal membranes and neural precursor cells from α-syn-deficient mice or transgenic mice expressing human α-syn. We first evaluated the recovery of the Ser(P)-129 epitope following either α-syn membrane binding or dissociation. We demonstrate a rapid turnover of Ser(P)-129 during both binding to and dissociation from synaptic membranes. Although the membrane binding of WT α-syn was insensitive to modulation of Ser(P)-129 levels by multiple strategies (the use of phosphomimic S129D and nonphosphorylated S129A α-syn mutants; by enzymatic dephosphorylation of Ser(P)-129 or proteasome inhibitor-induced elevation in Ser(P)-129; or by inhibition or stable overexpression of PLK2), PD mutant Ser(P)-129 α-syn showed a preferential membrane association compared with WT Ser(P)-129 α-syn. Collectively, these data suggest that phosphorylation at Ser-129 is dynamic and that the subcellular distribution of α-syn bearing PD-linked mutations, A30P or A53T, is influenced by the phosphorylation state of Ser-129.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Visanji</LastName><ForeName>Naomi P</ForeName><Initials>NP</Initials><AffiliationInfo><Affiliation>Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Ontario M5S 3H2, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wislet-Gendebien</LastName><ForeName>Sabine</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Oschipok</LastName><ForeName>Loren W</ForeName><Initials>LW</Initials></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Gang</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Aubert</LastName><ForeName>Isabelle</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Fraser</LastName><ForeName>Paul E</ForeName><Initials>PE</Initials></Author><Author ValidYN="Y"><LastName>Tandon</LastName><ForeName>Anurag</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MOP84527</GrantID><Agency>Canadian Institutes of Health Research</Agency><Country>Canada</Country></Grant><Grant><GrantID>089703</GrantID><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MOP84501</GrantID><Agency>Canadian Institutes of Health Research</Agency><Country>Canada</Country></Grant><Grant><GrantID>FRN 93603</GrantID><Agency>Canadian Institutes of Health Research</Agency><Country>Canada</Country></Grant><Grant><GrantID>MC_G1000734</GrantID><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>08</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biol Chem</MedlineTA><NlmUniqueID>2985121R</NlmUniqueID><ISSNLinking>0021-9258</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000939">Epitopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.-</RegistryNumber><NameOfSubstance UI="D011494">Protein Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.-</RegistryNumber><NameOfSubstance UI="C496126">PLK2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D017346">Protein-Serine-Threonine Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.21</RegistryNumber><NameOfSubstance UI="C444640">serum-inducible kinase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>EMBO Rep. 2002 Jun;3(6):583-8</RefSource><PMID Version="1">12034752</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Cell Biol. 2002 Feb;4(2):160-4</RefSource><PMID Version="1">11813001</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurosci Lett. 2003 Jan 23;336(3):155-8</RefSource><PMID Version="1">12505616</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Biol Chem. 2003 Apr 25;278(17):15313-8</RefSource><PMID Version="1">12586824</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mol Cell Biol. 2003 Aug;23(16):5556-71</RefSource><PMID Version="1">12897130</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Science. 2003 Dec 5;302(5651):1772-5</RefSource><PMID Version="1">14657500</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Proc Natl Acad Sci U S A. 2004 Jun 1;101(22):8331-6</RefSource><PMID Version="1">15155902</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurosci. 2004 Jul 28;24(30):6715-23</RefSource><PMID Version="1">15282274</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Brain Res Mol Brain Res. 1991 Oct;11(3-4):335-43</RefSource><PMID Version="1">1661825</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mol Cell Biol. 1997 Jun;17(6):3408-17</RefSource><PMID Version="1">9154840</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Proc Natl Acad Sci U S A. 1998 May 26;95(11):6469-73</RefSource><PMID Version="1">9600990</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neuron. 1998 Jul;21(1):147-54</RefSource><PMID Version="1">9697859</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Curr Biol. 1998 Aug 27;8(17):971-4</RefSource><PMID Version="1">9742400</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Biol Chem. 1998 Oct 9;273(41):26292-4</RefSource><PMID Version="1">9756856</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Virol. 1998 Nov;72(11):8463-71</RefSource><PMID Version="1">9765382</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>FEBS Lett. 1998 Nov 27;440(1-2):67-70</RefSource><PMID Version="1">9862427</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>FEBS J. 2005 Mar;272(6):1386-400</RefSource><PMID Version="1">15752356</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Neurosci. 2005 May;8(5):657-63</RefSource><PMID Version="1">15834418</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Annu Rev Biochem. 2005;74:29-52</RefSource><PMID Version="1">15952880</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Biol Chem. 2005 Sep 9;280(36):31664-72</RefSource><PMID Version="1">16020543</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurosci. 2005 Nov 23;25(47):10913-21</RefSource><PMID Version="1">16306404</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mol Cell Neurosci. 2006 Mar;31(3):560-73</RefSource><PMID Version="1">16426857</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurol Res. 2006 Jul;28(5):505-12</RefSource><PMID Version="1">16808880</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Biol Chem. 2006 Oct 6;281(40):29739-52</RefSource><PMID Version="1">16847063</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Biol Chem. 2006 Oct 27;281(43):32148-55</RefSource><PMID Version="1">16926154</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Curr Biol. 2007 Feb 20;17(4):316-22</RefSource><PMID Version="1">17291758</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Protoc. 2006;1(1):234-40</RefSource><PMID Version="1">17406238</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>FEBS Lett. 2007 Oct 2;581(24):4711-7</RefSource><PMID Version="1">17868672</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Exp Neurol. 2008 Jan;209(1):5-11</RefSource><PMID Version="1">17603039</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Proc Natl Acad Sci U S A. 2008 Jan 15;105(2):763-8</RefSource><PMID Version="1">18178617</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neuropathol Exp Neurol. 2008 May;67(5):402-16</RefSource><PMID Version="1">18451726</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Biol Chem. 2008 Jun 13;283(24):16895-905</RefSource><PMID Version="1">18343814</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Biochim Biophys Acta. 2008 Oct;1783(10):1767-80</RefSource><PMID Version="1">18634833</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>BMC Neurosci. 2008;9:92</RefSource><PMID Version="1">18808659</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Biol Chem. 2009 Jan 30;284(5):2598-602</RefSource><PMID Version="1">19004816</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neuropathol Exp Neurol. 2009 May;68(5):515-24</RefSource><PMID Version="1">19525899</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Biol Chem. 2010 Jan 22;285(4):2807-22</RefSource><PMID Version="1">19889641</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurotox Res. 2010 Apr;17(3):215-27</RefSource><PMID Version="1">19653055</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Science. 2010 Sep 24;329(5999):1663-7</RefSource><PMID Version="1">20798282</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Trends Neurosci. 2010 Dec;33(12):559-68</RefSource><PMID Version="1">20961626</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurosci Res. 2011 Feb;89(2):231-47</RefSource><PMID Version="1">21162130</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Biol Chem. 2000 Jan 7;275(1):390-7</RefSource><PMID Version="1">10617630</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Biol Chem. 2000 Aug 25;275(34):26515-22</RefSource><PMID Version="1">10852916</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Biol Chem. 2000 Nov 3;275(44):34328-34</RefSource><PMID Version="1">10915790</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Mol Biol. 2001 Apr 6;307(4):1061-73</RefSource><PMID Version="1">11286556</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Biochemistry. 2001 Sep 25;40(38):11604-13</RefSource><PMID Version="1">11560511</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Biol Chem. 2002 Dec 13;277(50):49071-6</RefSource><PMID Version="1">12377775</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D019943" MajorTopicYN="N">Amino Acid Substitution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000939" MajorTopicYN="N">Epitopes</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016631" MajorTopicYN="N">Lewy Bodies</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020125" MajorTopicYN="N">Mutation, Missense</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020734" MajorTopicYN="N">Parkinsonian Disorders</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011494" MajorTopicYN="N">Protein Kinases</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D021381" MajorTopicYN="N">Protein Transport</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017346" MajorTopicYN="N">Protein-Serine-Threonine Kinases</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013570" MajorTopicYN="N">Synaptic Membranes</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051844" MajorTopicYN="N">alpha-Synuclein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><OtherID Source="NLM">PMC3195582</OtherID></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>8</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>8</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>12</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21849493</ArticleId><ArticleId IdType="pii">M111.253450</ArticleId><ArticleId IdType="doi">10.1074/jbc.M111.253450</ArticleId><ArticleId IdType="pmc">PMC3195582</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000B63 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000B63 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:21849493
|texte= Effect of Ser-129 phosphorylation on interaction of α-synuclein with synaptic and cellular membranes.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:21849493" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |